Insulin sparing effect of hydroxychloroquine in uncontrolled diabetes mellitus
Abstract
Hydroxychloroquine (HCQ) has a favorable glycemic effect that provides a rationale for its use in diabetes mellitus. Decreased insulin degradation and increased insulin sensitivity is suggested to contribute to the reduction in serum glucose levels. Herein, we present a case on the beneficial impact of HCQ on glycemic control in diabetes mellitus. A 69-year old female suffering from type 2 diabetes mellitus presented to the clinic for routine follow up. For management of diabetes she was taking glimepiride 4mg once daily, combination of metformin and sitagliptin (1000/50 mg) twice daily and 94 units of insulin/day. Baseline fasting plasma glucose (FPG) and postprandial plasma glucose (PPG) levels were 183 and 222 mg/dL respectively and glycosylated hemoglobin A (HbA1c) level was 8.4%. To achieve glycemic control HCQ 400 mg once daily was initiated as an add on antidiabetic drug. HBA1c level decreased to 6.9% at four months and to 6.8% at eight months after HCQ was utilized. FPG level decreased to 110 mg/dL at six months and to 114 mg/dL at eight months. PPG level decreased to 178 mg/dL at six months and 130 mg/dL at eight months. Thus the FPG level decreased by 69 mg/dL and PPG level decreased by 92 mg/dL respectively from baseline. Acknowledging the progressive positive response to antidiabetic agents, the insulin dose was decreased to 56 units/day at four months, 42 units/day at six months and 28 units/day at eight months. The case highlights the potential ability of HCQ to lower HbA1c and decrease insulin requirement in uncontrolled diabetic patients.
Keywords: hydroxychloroquinediabetes mellitusinsulinhyperglycemiaHbA1c
References
- Raheja BS, Kapur A, Bhoraskar A, et al. DiabCare Asia--India Study: diabetes care in India--current status. J Assoc Physicians India. 2001; 49: 717–722.
- Pareek A, Chandurkar N, Thomas N, et al. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone. Curr Med Res Opin. 2014; 30(7): 1257–1266.
- Wasko MC, Hubert HB, Lingala VB, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA. 2007; 298(2): 187–193.
- Quatraro A, Consoli G, Magno M, et al. Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug? Ann Intern Med. 1990; 112(9): 678–681.
- Sharma TS, Wasko MC, Tang X, et al. Hydroxychloroquine Use Is Associated With Decreased Incident Cardiovascular Events in Rheumatoid Arthritis Patients. J Am Heart Assoc. 2016; 5(1).
- Olsen NJ, Schleich MA, Karp DR. Multifaceted effects of hydroxychloroquine in human disease. Semin Arthritis Rheum. 2013; 43(2): 264–272.
- Marmor MF, Kellner U, Lai TYY, et al. American Academy of Ophthalmology, American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011; 118(2): 415–422.